title: APOL1 genotype, blood pressure, and survival in African Americans with nondiabetic nephropathy.
abstract: Several landmark trials have assessed the effects of aggressive hypertension control on the progression of nondiabetic chronic kidney disease. Results generally have been disappointing. With the realization that lowering blood pressure, including with renin-angiotensin system blockade, failed to reliably prevent end-stage kidney disease, studies now are analyzing longer-term effects of hypertension control on survival in chronic kidney disease. This commentary reviews the current findings and extends the discussion to apolipoprotein L1 gene by blood pressure (or gene by environment) interactions.
authors.affiliation: Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
authors.forename: Todd W
authors.initials: TW
authors.lastname: Robinson
authors.affiliation: Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. Electronic address: bfreedma@wakehealth.edu.
authors.forename: Barry I
authors.initials: BI
authors.lastname: Freedman
mesh_terms: D001741:Black or African American; D000075944:Apolipoprotein L1; D001053:Apolipoproteins / Q000235:genetics*; D001794:Blood Pressure; D005838:Genotype; D006801:Humans; D008075:Lipoproteins, HDL / Q000235:genetics; D012307:Risk Factors; D014481:United States
chemical_list: C108666:APOL1 protein, human; D000075944:Apolipoprotein L1; D001053:Apolipoproteins; D008075:Lipoproteins, HDL